A20 restricts NOS2 expression and intestinal tumorigenesis in a mouse model of colitis-associated cancer

David W. Basta, Mandy Vong, Adolat Beshimova, Brooke N. Nakamura, Iulia Rusu, Michael G. Kattah, Ling Shao

PII: S2772-5723(22)00156-X
DOI: https://doi.org/10.1016/j.gastha.2022.09.004
Reference: GASTHA 185

To appear in: Gastro Hep Advances

Received Date: 19 July 2021
Revised Date: 12 August 2022
Accepted Date: 12 September 2022

Please cite this article as: Basta DW, Vong M, Beshimova A, Nakamura BN, Rusu I, Kattah MG, Shao L, A20 restricts NOS2 expression and intestinal tumorigenesis in a mouse model of colitis-associated cancer, Gastro Hep Advances (2022), doi: https://doi.org/10.1016/j.gastha.2022.09.004.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2022 Published by Elsevier, Inc on behalf of the AGA Institute
Title: A20 restricts NOS2 expression and intestinal tumorigenesis in a mouse model of colitis-associated cancer

Running Title: A20 in colitis-associated cancer

Authors: David W. Basta, Mandy Vong, Adolat Beshimova, Brooke N. Nakamura, Iulia Rusu, Michael G. Kattah, Ling Shao

Division of Gastroenterology and Liver Disease, Department of Medicine, University of Southern California, Keck School of Medicine

#Corresponding Author: Ling Shao, M.D., Ph.D.

Email: lingshao76@gmail.com

Phone: 323-442-0248

Affiliation: Division of Gastroenterology and Liver Disease

Department of Medicine

University of Southern California, Keck School of Medicine

Address: 2011 Zonal Avenue

Hoffman Medical Research 600

Los Angeles, CA 90033

Funding: This work was supported by NIH R03 DK118178 (L.S). Additional support was provided by the USC Research Center for Liver Disease P30 DK048522 and the Norris Cancer Center P30 CA014089.

Conflicts of Interest: The authors disclose no conflicts.
Authors’ Contributions: DWB, BNN, and LS conceived and designed the study. DWB, MV, AB, BNN, IR, MGK, and LS participated in the generation, collection, assembly, analysis and interpretation of data. DWB, BNN, and LS wrote the manuscript. All authors approved the final version of the manuscript.

Word count: 2,100

Data Transparency Statement: Study material will be made available upon request from corresponding author.

Ethical Statement: The corresponding author, on behalf of all authors, jointly and severally, certifies that their institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and humane principles of research.
Abstract

Background & Aims: Colon cancer can occur sporadically or in the setting of chronic inflammation, such as in patients with inflammatory bowel disease. We previously showed that A20, a critical negative regulator of TNF-signal transduction, could regulate sporadic colon
cancer development. In this report, we investigate whether A20 also acts as a tumor suppressor in a model of colitis-associated cancer.

**Methods:** Colitis and colitis-associated tumors were induced in wild type (WT) and A20 intestinal epithelial cell-specific knockout (A20dIEC) mice using dextran sodium sulfate and azoxymethane (AOM-DSS). Clinicopathologic markers of inflammation were assessed in conjunction with colonic tumor burden. Gene expression analyses and immunohistochemistry were performed on colonic tissue and intestinal enteroids. Nitric oxide (NO) production and activity were assessed in whole colonic lysates and mouse embryonic fibroblasts.

**Results:** A20dIEC mice develop larger tumors after treatment with AOM-DSS than WT mice. In addition to elevated markers of inflammation, A20dIEC mice have significantly enhanced expression of inducible nitric oxide synthase (iNOS), a well-known driver of neoplasia. Enhanced iNOS expression is associated with the formation of reactive nitrogen species and DNA damage. Loss of A20 also enhances NO-dependent cell death directly.

**Conclusions:** Mechanistically, we propose that A20 normally restricts TNF-induced NFκB-dependent production of iNOS in intestinal epithelial cells, thereby protecting against colitis-associated tumorigenesis. We also propose that A20 plays a direct role in regulating NO-dependent cell death.

**Keywords:** colon; ulcerative colitis; inflammation; nitric oxide; A20; tnfaip3; tumor
**Introduction**

Colorectal cancer (CRC) is the third most common cancer and the third leading cause of cancer-related death in the United States. CRC accounts for over fifty-thousand deaths in the US annually, while in 2017, the National Cancer Institute estimated that there were over 1 million Americans living with CRC. Although mortality from CRC has been declining overall in the US, death rates are rising among younger individuals (1). CRC is also more common among African Americans and significant disparities in outcomes exist based on race and ethnicity, as well as socioeconomic status (2). Recent estimates suggest that the economic burden of CRC exceeded $16 billion in 2018 (3). Overall, CRC remains a significant problem and new treatments are still needed.

CRC can occur sporadically in the general population or associated with chronic inflammation. One well-known predisposing factor associated with CRC development is inflammatory bowel disease (IBD). Patients with IBD have as much as a six-fold increased risk of developing CRC compared to the general population (4, 5). Moreover, this colitis-associated cancer accounts for 10-15% of the mortality associated with IBD (6).

The pathophysiology of sporadic colon cancers and colitis-associated cancers is distinct. Seminal work from Dr. Vogelstein and colleagues demonstrated a sequence of mutations commonly found in sporadic colon cancers proceeding from an initiating mutation in adenomatous polyposis coli (APC) progressing to mutations in KRAS and finally, p53 (7–11). Studies in colitis-associated cancer show that specific genetic mutations also correlate with the adenoma to carcinoma progression (12), however the nature and order of these mutations are altered. Indeed,
in contrast to sporadic colon cancers, loss of p53 appears to be an early event in colitis-associated cancers and is seen in up to a third of biopsy specimens with only low-grade dysplasia (13, 14). In contrast, APC mutations are uncommon in colitis-associated cancers and dysplasia, occurring in less than 10% of cases in some series (15, 16).

Colitis-associated cancers may be accelerated by dysregulation of the nuclear factor-kappa B (NFkB) signaling pathway. The NFkB pathway is a critical regulator of both inflammation and cell death (17, 18). Major activators of NFkB are the TNF-superfamily, including TNF, TRAIL, and FAS, as well as the toll-like receptor family and reactive oxygen species (19). Multiple studies have shown that tumor growth and neoplastic progression depend on NFkB signals (20). NFkB p65 has been shown to be overexpressed in human colorectal cancer tissues (21) potentially enhancing tumorigenesis by upregulating anti-apoptotic genes. Additionally, overactivity of the NFkB pathway is sufficient to drive colon carcinogenesis in mice (22).

A20, encoded by tumor necrosis factor alpha induced protein 3 (TNFAIP3), is a ubiquitin binding and editing enzyme that negatively regulates inflammation (23–25). Defects in A20 in humans cause a systemic inflammatory syndrome, while A20 defects in mice cause early lethality due to widespread inflammation (26, 27). A20 has been shown to be a critical regulator of NFkB signaling through the regulation of proximal TNF-receptor signaling (23, 28). Of note, although the majority of the literature supports the role of A20 as a negative regulator of inflammation and apoptosis, a recent report demonstrated that, conversely, overexpression of A20 can promote TNF-induced and RIPK1-dependent inflammation and apoptosis in intestinal epithelial cells (29).
A20 is a tumor suppressor for multiple types of malignancy. Deletion or downregulation of A20 has been found in multiple B-cell lymphoma subtypes (30–34). Similarly, A20 dysregulation has been shown to contribute to the initiation or progression of gastric cancer (35, 36), breast cancer (37), esophageal cancer (38, 39), thyroid cancer (40) and colon cancer (41, 42). We previously reported that A20 could act as a tumor suppressor in a murine model of sporadic colorectal cancer (42).

In this report, we investigated the effect of intestinal epithelial cell specific A20 deletion in a well-characterized AOM-DSS model of colitis-associated cancer. We found that epithelial A20 knockout mice had increased tumor burden. Enteroid cultures from A20 knockout mice revealed strong induction of inducible nitric oxide synthase (iNOS) in response to inflammatory signals, which were confirmed in vivo. In addition to restricting TNF-induced iNOS, we also show that A20 may directly regulate nitric oxide-dependent cell death.

**Results**

To investigate the role of A20 in colitis-associated cancer, we used a mouse strain with an intestinal epithelial cell-specific knockout of A20 (A20dIEC). Eight to twelve week-old WT and A20dIEC mice were treated with the mutagen azoxymethane (AOM) and the sugar dextran sodium sulfate (DSS) to induce colitis-associated tumorigenesis. AOM was administered on Day 0 followed by three rounds of DSS treatment each lasting 5 days and separated by a 16-day rest period (Figure 1A). Mice were culled after the final rest period on Day 70 and the colon, spleen, mesenteric lymph nodes, and serum were harvested for downstream analyses.
We observed no significant differences between WT and A20dIEC mice when assessing traditional markers of DSS-induced intestinal inflammation, including weight loss, colon length, spleen weight, or clinical score (Figure 1B-E). However, A20dIEC mice appeared to have a generally more immunoreactive profile compared to WT mice after AOM-DSS treatment, as suggested by significantly higher serum levels of TNF and elevated IL-12 (Figure 1F and G). Additionally, A20dIEC mice had lower levels of naïve splenic CD4 T-cells and higher levels of activated splenic monocytes (Figure 1H and I). Together, these results suggest that loss of A20 expression specifically in intestinal epithelial cells supports systemic immune activation in the AOM-DSS colitis model of colon cancer, although loss of A20 does not result in worsening of traditional clinicopathologic markers of DSS-induced intestinal inflammation under our experimental conditions.

WT and A20dIEC mice had similar numbers of colonic tumors on day 70 (Figure 2A). However, despite similar tumor numbers, the average tumor size was larger in A20dIEC mice compared to WT, resulting in an increased tumor burden (Figure 2B and C). Histologic examination revealed that colonic tumors were grossly similar between WT and A20dIEC mice in regards to the severity of dysplasia and the level of invasiveness (Figure 2D-I). These results suggest that A20 slows tumor growth and overall tumor burden without affecting tumor formation in the AOM-DSS colitis model of colon cancer.

To identify molecular mechanisms underlying the increased tumor burden in A20dIEC mice, we first measured global gene expression using RNA-seq in WT and A20dIEC-derived small intestinal (SI) enteroids stimulated with TNF. Among the most differentially expressed genes was NOS2, encoding the inducible nitric oxide synthase (iNOS). Reads mapping to NOS2 were
significantly enriched in A20dIEC mice compared to WT (Figure 3A). We also confirmed increased expression of NOS2 in A20dIEC-derived colonic enteroids by qRT-PCR under both TNF-stimulated and unstimulated conditions (Figure 3B). Importantly, expression of TNFAIP3, the gene encoding A20, was detected only in WT colonic enteroids, where its expression increased in a TNF-dependent manner (Figure 3C). This finding confirmed that A20 was successfully depleted in our A20dIEC-derived colonic enteroids and that its expression is controlled by TNF signaling under our experimental conditions. We also observed increased expression of IkBa in A20dIEC-derived colonic enteroids (Figure 3D). IkBa is positively regulated by NFkB and served as a positive control for TNF stimulation (43). Increased NOS2 gene expression was correlated with increased iNOS functional activity, as measured by a TNF-dependent increase in the reactive nitrogen species (RNS) nitrite specifically in the supernatant of A20dIEC-derived colonic enteroids (Figure 3E). To determine whether the increased NOS2 expression in A20dIEC-derived colonic enteroids is associated with elevated expression of iNOS in vivo, we measured iNOS protein levels by Western blot in intestinal epithelial cell (IEC) extracts isolated from colonic tissue of WT and A20dIEC mice treated with one round of DSS. We observed a DSS-dependent increase in expression of iNOS in A20dIEC mice relative to WT (Figure 4A). Increased expression was corroborated by immunohistochemical staining of tissue sections of colonic epithelium (Figure 4B and C). Surprisingly, iNOS expression in A20dIEC mice was significantly increased compared to WT in the normal colonic epithelium but not in sections of colonic tumors (data not shown). Based on these results, we conclude that A20 negatively regulates NOS2 gene expression and RNS production in intestinal tissues, potentially via inhibition of NFkB signaling.
RNS are known to cause DNA damage and apoptosis, contributing to tumor formation and tumor progression (44). Accordingly, we observed increased expression of the DNA damage marker p53 in whole colonic lysates from A20dIEC mice (Figure 5A). We also found that A20-deficient mouse embryonic fibroblasts (MEFs) showed increased cell death when treated with exogenous NO (Figure 5B). This latter finding was surprising because it suggests that in addition to regulating the production of RNS via NOS2 gene expression, A20 independently protects cells against RNS-mediated toxicity. In agreement with this finding, loss of A20 was associated with enhanced activation of intrinsic apoptosis in the presence of NO in both MEFs and colonic enteroids (Figure 5C-F). Together, these findings suggest that A20 protects against RNS-mediated DNA damage and apoptosis in the setting of colitis-associated cancer and provide a potential explanation for the increased tumor burden in mice lacking this critical regulator.

**Discussion**

The underlying pathophysiology of colon cancers that arise in the setting of inflammation is poorly understood. One factor that may play a role is abnormal production or function of the small molecule nitric oxide (NO). NO is produced by three isozymes of nitric oxide synthase, nNOS/NOS1, iNOS/NOS2, and eNOS/NOS3. Previous reports have shown focal NO induction in the intestinal epithelium of patients with ulcerative colitis (45) and our data strongly corroborates the role of enhanced NO production in the setting of chronic inflammation. The fact that our final tissue analysis was performed 16 days after the final DSS cycle (Figure 4B and C) also suggests that a sustained upregulation of iNOS occurs in A20dIEC mice. Taken together, our data supports the usefulness of the AOM-DSS model for studying A20-regulated NO production and activity in the intestine.
NO may promote CRC development through multiple mechanisms. Reactive nitrogen species such as peroxynitrite can cause DNA mutations directly, but may also inhibit the function of DNA repair proteins or stimulate angiogenesis (46–48). Additionally, NO may induce cell death directly through a mitochondrial-dependent pathway (49). Our data shows that loss of A20 may facilitate carcinogenesis by potentiating the expression of iNOS and by enhancing the lethality of the resulting increase in NO production.

Excess apoptosis has been noted in inflammatory diseases such as IBD (50, 51) and graft-versus-host disease (52, 53), while dysregulated apoptosis could contribute to the development of colorectal cancer (54). Our finding that A20 may regulate NO-induced apoptosis independently of its role in regulating NO production is intriguing as a potential contributor to these conditions. Although low levels of NO are known to inhibit apoptosis, high levels can trigger apoptosis through multiple mechanisms (55). Covalent incorporation of NO (s-nitrosylation) has been shown to alter the function of death receptors such as TRAIL (56) and Fas (57), but can also alter the function of downstream death-inducing molecules including the proapoptotic caspase-3 and caspase-8 (58). Alternatively, s-nitrosylation of NFkB can inhibit the expression of anti-apoptotic proteins (59). A20 could potentially regulate NO-induced cell death through dysregulation of NFkB signaling or alternatively through its known roles in regulating caspase-8 containing death complexes via regulation of RIPK1 (23, 25, 60, 61). However, a detailed mechanistic explanation of the regulatory role A20 plays in apoptosis is the subject of ongoing investigations.
Surprisingly, iNOS expression was specifically increased in the normal surrounding colonic epithelium but not within the tumors of A20dIEC mice relative to WT (Figure 4B and C and data not shown). This finding suggests that increased iNOS expression may promote early tumor formation in normal colonic epithelium but play a less important role in tumor progression. However, our finding that the total number of tumors was similar between WT and A20dIEC mice at the end of the experiment seemingly contradicts this notion (Figure 2A). The observed increase in tumor size despite similar tumor numbers instead suggests that increased iNOS expression accelerates tumor progression without affecting net tumor incidence. A careful examination of the dynamics of tumor formation and progression will shed more light on this observation and perhaps resolve the apparent discrepancy.

Overall, our findings suggest that A20 acts as a tumor suppressor in colitis-associated cancers by regulating NFkB-dependent expression of iNOS and the ensuing production of RNS. Although direct inhibition of nitric oxide production would likely have pleiotropic effects, our results raise the intriguing possibility that inhibition of iNOS activity, or the quenching of RNS byproducts, could serve an adjunctive therapeutic role in the treatment of colitis-associated cancer. Additionally, our findings support an independent role for A20 in protecting cells against RNS-mediated lethality (Figure 6).

Methods

Antibodies and Reagents: DETA-NONOate was obtained from Abcam (Cambridge, UK). Antibodies to A20, cleaved-caspase 3, iNOS and PARP were obtained from Cell Signaling Technologies (Danvers, MA). GAPDH was obtained from Millipore Sigma (Burlington, MA). p53 was obtained from Santa Cruz Biotechnology (Dallas, TX). Anti-rabbit Cy3 was obtained
from Jackson ImmunoResearch (West Grove, PA). DAPI and Phalloidin were obtained from Thermo Fisher Scientific and Abcam, respectively. Recombinant mTNF was obtained from R&D Systems (Minneapolis, MN). Cycloheximide was obtained from Sigma-Aldrich (St. Louis, MO). Cell Titer Glo was obtained from Promega (Madison, WI). Dextran sodium sulfate (DSS 40 kDa) was obtained from Chem-Impex Int’l INC (Wood Dale, IL). Azoxymethane (AOM) was obtained from Sigma (St. Louis, MO).

Mice: A20FL mice were generated as described previously (62). Wild-type and A20-deficient mouse embryonic fibroblasts were generated as described previously (63). Villin-Cre mice were purchased from Jackson Labs. Villin-ERT2-Cre mice were originally obtained from Dr. Sylvie Robine (64).

Induction of colitis-associated tumors: AOM was injected intraperitoneally into eight to twelve week-old WT and A20dIEC mice at a concentration of 10 mg/kg body weight on experimental day 0. Three cycles of DSS were administered at a concentration of 1.75%. Tumor number and burden were determined at four months of age with the aid of a stereomicroscope equipped with a sizing reticle (Klarman Rulings, Litchfield NH). The clinical score was calculated as the average of the combined score of weight loss, stool consistency, and bleeding following each DSS cycle. Each category was scored as followed: weight loss: 0 (no loss), 1 (1-5%), 2 (5-10%), 3 (10-20%), and 4 (>20%); stool consistency: 0 (normal), 2 (loose stool), and 4 (diarrhea); and bleeding: 0 (no blood), 2 (visual blood on bedding), and 4 (gross bleeding, blood around anus) (65). All animal studies were conducted in accordance with the University of Southern California (IACUC #20192) Institutional Animal Care and Use Committee.

Histology/Immunohistochemistry: Formalin fixed paraffin sections were deparaffinized and rehydrated. Antigen retrieval was performed with 10 mM sodium citrate buffer, pH 6.0 in a 95
°C water bath for 30 min. Tissue was permeabilized with 0.3% Tween-20 in 1X PBS for 45 min at 37 °C. Sections were blocked using SEA BLOCK Blocking Buffer (Thermo Fisher, Watham, MA) for 1 h at room temperature. Primary antibodies were incubated overnight at 4 °C in blocking buffer. Slides were incubated for 1 h at room temperature with secondary antibody and counter stained with Phalloidin-iFluor 488 (Abcam) and DAPI (Thermo Fisher) and mounted with ProLong Gold (ThermoFisher) and glass coverslips sealed with nail polish. Images were captured using a Leica TCS SP5 multiphoton confocal microscope and quantified using Fiji (66). iNOS fluorescence was quantified by normalizing the total integrated density (Alexa 594) to the total surface area of colonic epithelium.

**Flow Cytometry:** Cells were resuspended to a concentration of 1x10^6 cells/ml. Cells were stained with antibodies CD44-FITC, CD69-PE, CD4-PE/Cy7, CD62L-APC, CD8-vFluor450, CD25-APC/Cy7, CD80-APC, CD86-PE, CD11b-PE/Cy7, F4/80-APC, IA/E-vFluor 450, GR 1-APC/Cy7, and B220-PerCP/Cy5.5 (Tonbo Bioscience, San Diego, CA) and Zombie Yellow Fixable Viability Kit (BioLegend). Cells were incubated in the dark at room temperature for 30 min. Flow cytometry acquisition was performed on a FacsVantage (BD Biosciences, San Jose, CA) and analyzed using FlowJo software (BD Biosciences, San Jose, CA).

**ELISA:** IL-12 and TNF cytokine ELISA was performed according to the manufacturer’s instructions (Peprotech, Canbury, NJ). Briefly, ELISA plates (Corning) were coated with capture antibody diluted to 1 µg/ml. Non-specific binding was blocked using PBS containing 1% bovine serum albumin (Sigma). Cell supernatants were added and incubated at room temperature for 2 h. Detection antibody was added at a concentration of 500 ng/ml for 2 h, followed by an avidin-HRP conjugate at a dilution of 1:2000 for 30 min. Plates were washed between each step 5X
with PBS containing 0.05% Tween-20 (Sigma P9416). Plates were developed using TMB substrate and read using a Fluostar Omega (BMG Labtech, Cary, NC).

**Enteroids:** Large and small intestine enteroids were isolated as previously described (67, 68).

A20FL/FL VillinERCre+ and A20FL/FL VillinERCre- mice were euthanized according to IACUC approved protocols. Colons and small intestines from each mouse were removed and gently flushed with cold PBS. They were then cut open lengthwise and cut into 2 mm pieces. Intestinal pieces were washed 15X with ice cold PBS by pipetting the suspended pieces up and down three times. Tissue pieces were then incubated in Gentle Cell Dissociation Reagent (StemCell) for 20 min at room temperature. Fractions were then collected from the intestinal pieces in 0.1% BSA/PBS. Fractions that contained crypts were used for enteroid culture. The crypts were resuspended in a 1:1 mixture of Matrigel (Corning) and complete Intesticult Media (StemCell), which was then plated in a pre-warmed 24 well plate and covered with 750 µl complete Intesticult. The medium was changed every 2-3 days and enteroids were split every 7-10 days. Enteroids were incubated with 4-OH tamoxifen for 72 h to knockout A20. Following knockout, enteroids were treated with rmTNF at 10 ng/ml in complete Intesticult for 24 h.

**Nitrite measurement:** Total nitrite concentrations were measured via Parameter kit (R&D systems) according to the manufacturer’s instructions. Briefly, dilutions of supernatants from enteroid cultures, standards or blanks were added to 96 well plates. Griess reagents I and II were added and incubated for 10 min at room temperature. Optical density of each sample was recorded at both 540 and 690 nm on a Fluostar Omega plate reader.

**Western blot:** Colonic tissue was flash frozen in liquid nitrogen and homogenized using a mortar and pestle. For western blot, pellets from these homogenates were lysed in ice cold buffer containing 200 µg/ml digitonin (150 mM NaCl and 50 mM HEPES) and the Roche complete
mini protease inhibitor cocktail for 20 min, then cleared by centrifugation. Lysates were prepared
identically for enteroids and mouse embryonic fibroblasts. Protein concentrations were
determined by BCA assay (Thermo). Samples were mixed with NuPage loading buffer and
NuPage sample reducing agent (Invitrogen) and resolved on 4-12% Bis-Tris (Invitrogen) gels
then transferred to 0.4 μM PVDF (Millipore). Western blot development was performed using
the Clarity chemiluminescent substrate (Bio-Rad, Hercules, CA) and imaged on a Chemidoc
touch (Bio-Rad, Hercules, CA) system. Analysis was performed using Image Lab (Bio-Rad,
Hercules, CA).

RNA-seq: Total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany).
RNA quality was determined by Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA). Libraries
were prepared from 500 ng of total RNA using a Kapa mRNA HyperPrep Kit for Illumina
platforms (Kapa Biosystems, Inc., Wilmington, MA, USA). Final library products were
quantified using the Qubit 2.0 Fluorometer (Thermo Fisher Scientific Inc., Waltham, MA, USA),
and the fragment size distribution was determined with the Bioanalyzer 2100. Equimolar
concentrations of the libraries were then pooled and the final pool was quantified via qPCR using
the Kapa Biosystems Library Quantification Kit according to the manufacturer’s instructions.
The pool was sequenced in an Illumina HiSeq 2500 platform (Illumina, San Diego, CA, USA),
in Rapid Single-Read 75 cycles format, targeting at least 30 million reads per sample. The
preparation of the libraries and the sequencing was performed at the UPC Genome Core
(University of Southern California, Los Angeles, CA, USA).

Initial read quality and adaptor content of FASTQ files were assessed with FastQC (69). Reads
were then trimmed based on quality score and adaptor sequences removed using Trimmomatic
(70). After filtering, surviving reads were checked again in FastQC to ensure that only high-
quality transcriptome reads were put into the analysis pipeline. These high-quality reads were
mapped to the human genome (ver. GRCh38.p7) using the ultra-fast aligner STAR (71); the
same software was used to obtain uniquely mapping read counts for each gene feature included
in a Gene Transfer Format (GTF) file. Both the genome and the GTF file were downloaded from
the GENCODE database (https://www.gencodegenes.org).

Quantitative PCR: mRNA was extracted using Trizol (Invitrogen) and the DirectZol column
purification kit (Zymo). First strand cDNA synthesis was performed using Maxima H-
Mastermix (Thermo). Primers to NOS2, A20, and NFKBIA were designed using IDT Primer
Quest (Table 1). Quantitative PCR was performed using TB Green Premix Ex Taq II Rox plus
(Takara, Japan, Lot #AJF1254A) and run on a CFX-384 Touch Real Time PCR Detection
System (Bio-Rad, Hercules, CA).

Statistical analysis: Statistical analysis was performed with Graphpad Prism 4 (Graphpad
Software, San Diego, CA). Comparisons between two groups were performed by two-tailed
unpaired Student’s t-test. Multigroup comparisons were performed by one-way analysis of
variance (ANOVA). p < 0.05 was used as the threshold for statistical significance. All
experiments shown are representative of at least three independent experiments.

All authors had access to the study data and had reviewed and approved the final manuscript.

Acknowledgements

This work was supported by NIH R03 DK118178 (L.S). Additional support was provided by the
USC Research Center for Liver Disease P30 DK048522 and the Norris Cancer Center P30
CA014089.
**Figure Legends**

Figure 1. Phenotype of IEC-specific A20 deficient mice treated with AOM-DSS. A) Schematic diagram of experimental design. Mice were injected at day 0 with 10 mg/kg azoxymethane (AOM). Three rounds of treatment were performed with 1.75% dextran sodium sulfate (DSS) with a sixteen day interval between each treatment. Mice were euthanized and tissues collected after a total of 70 days. B) Body weight in wild-type (boxes) and A20dIEC (triangles) expressed as a percentage of initial body weight. Periods of treatment with DSS are shown on the x-axis. Only upper error bars for wild-type and lower error bars for A20dIEC mice are shown for clarity. C) Colon length normalized to total body weight at the conclusion of the experiment on day 70 in wild-type (WT) and A20dIEC (KO) mice. D) Average clinical scores for wild-type (black bars) and A20dIEC (open grey bars) during each cycle of DSS. Clinical scores range from 0 to 4 (see methods). E) Spleen weights normalized to total body weight at the conclusion of the experiment on day 70 in wild-type (WT) and A20dIEC (KO) mice. F) Serum TNF from wild-type (WT) and A20dIEC (KO) mice at the conclusion of the experiment on day 70 as measured by ELISA. G) Serum IL-12 from wild-type (WT) and A20dIEC (KO) mice at the conclusion of the experiment on day 70 as measured by ELISA. H) Naïve splenic T-cells (CD3+CD4+CD62L+CD44-) in wild-type (WT) and A20dIEC (KO) mice as determined by flow cytometry. Results are displayed as a percentage of total CD4+ T-cells. I) Mean fluorescence intensity of MHC class II expression on CD11b+Gr-1low monocytes in the spleen of wild-type (WT) and A20dIEC (KO) mice as determined by flow cytometry. * p < 0.05, ** p < 0.01. Comparison between two groups were performed by two-tailed unpaired student’s t-test. Multigroup comparison were performed by one-way ANOVA. n=3-5 wild-type and n=3-5.
407 A20dIEC mice per experiment. Experiments were repeated three times. In total 11 wild-type
408 males, 4 wild-type females, 9 A20dIEC males, and 5 A20dIEC females were analyzed.
409
410 Figure 2. Increased tumor burden in A20dIEC mice treated with AOM-DSS. A) Tumor number
411 per mouse in wild-type (WT) and A20dIEC (KO) mice. B) Average tumor size in wild-type
412 (WT) and A20dIEC (KO) mice. C) Total tumor burden per mouse in wild-type (WT) and
413 A20dIEC (KO) mice. Tumor burden was calculated by multiplying the tumor number by the
414 average tumor size. D-I) Representative histologic images from wild-type (D,E,F) and A20dIEC
415 (G,H,I) mice. Normal areas of colon (D,G), areas of dysplasia (E,H) are shown at 20X
416 magnification. Areas of dysplasia shown at 40X magnification (F,I). * p < 0.05, ** p < 0.01.
417 Comparison between two groups were performed by two-tailed unpaired student’s t-test.
418 Multigroup comparisons were performed by one-way ANOVA. n=3-5 wild-type and n=3-5
419 A20dIEC mice per experiment as in Figure 1. Experiments were repeated three times.
420
421 Figure 3. Upregulation of NOS2 in IEC-specific A20 deficient enteroids after an inflammatory
422 stimulus. A) The top five most highly upregulated (top) and downregulated (bottom) genes in
423 wild-type versus A20dIEC derived small-intestinal enteroids stimulated with TNF (10 ng/ml) for
424 24 hours determined by RNAseq. Arrow highlights the expression of inducible nitric oxide
425 (iNOS/NOS2). B-D) Expression of iNOS (B), A20 (C), and IKBa (D) in wild-type (WT) and
426 A20dIEC (KO) derived colonic enteroids stimulated with and without TNF (10 ng/ml) for 24 h.
427 E) Total nitrite level in the supernatants of wild-type (WT) and A20dIEC (KO) derived colonic
428 enteroids stimulated with and without TNF (10 ng/ml) for 24 hours as determined by Griess
429 reaction. ** p < 0.01. Comparison between two group were performed by two-tailed unpaired
student’s t-test. Multigroup comparisons were performed by one-way ANOVA. All experiments shown are representative of at least three independent experiments.

Figure 4. NOS2 is upregulated in the epithelial cells of IEC-specific A20 deficient mice treated with AOM-DSS. A) Expression of iNOS, A20, and GAPDH (loading control) by western blot of intestinal epithelial cells isolated from colonic tissue in wild-type or A20dIEC mice treated for three days with dextran sodium sulfate (DSS) or untreated. B) Representative immunofluorescence images taken from wild-type or A20dIEC colons after AOM-DSS treatment. C) Quantification of iNOS expression in the colonic epithelium of wild-type (WT) or A20dIEC (KO) mice after AOM-DSS treatment. * p < 0.05. Comparisons between two groups were performed by two-tailed unpaired student’s t-test. Multigroup comparisons were performed by one-way ANOVA. All experiments shown are representative of at least three independent experiments.

Figure 5. A20 deficiency enhances susceptibility to DETA-NO cell death. A) Expression of p53, A20, and GAPDH (loading control) in wild-type or A20dIEC whole colonic lysates from mice treated with AOM-DSS. B) Cell death in wild-type or A20-deficient (A20KO) mouse embryonic fibroblasts (MEFs) treated with TNF (10 ng/ml) and cycloheximide (CHX, 10 µg/ml) or DETA-NO at the indicated concentrations for 24 hours as measured by Cell-Titer Glo assay. C) Expression of PARP, cleaved-caspase 3 (Cl-Casp3), A20, and GAPDH (loading control) in wild-type (WT) and A20-deficient (A20KO) mouse embryonic fibroblasts (MEFs) stimulated with TNF (10 ng/ml) and cycloheximide (CHX, 10 µg/ml) or DETA-NO (200 µM) for the indicated times as measured by western blot. Open arrowhead and closed arrowhead highlight full-length and cleaved PARP, respectively. D) Expression of PARP, cleaved-caspase 3 (Cl-Casp3), A20,
and GAPDH (loading control) in wild-type (WT) and A20-deficient (KO) colonic enteroids stimulated with DETA-NO (200 μM) for the indicated times as measured by western blot. Open arrowhead and closed arrowhead highlight full-length and cleaved PARP respectively. E,F) Densitometry of cleaved PARP (E) and cleaved caspase-3 (F) from western blot shown in D. ** p < 0.01. Comparisons between two groups were performed by two-tailed unpaired student’s t-test. Multigroup comparisons were performed by one-way ANOVA. All experiments shown are representative of at least three independent experiments.

Figure 6. Proposed model for the regulation of colitis-associated cancer by intestinal epithelial cell expression of A20. Inflammation, for example mediated by TNF, leads to the NFκB-dependent upregulation of inducible nitric oxide synthase (iNOS/NOS2). iNOS can produce reactive nitrogen species which can lead to DNA damage and cell death potentially promoting carcinogenesis. A20 is an early NFκB induced gene and can dampen further inflammation by restricting TNF-receptor signaling in a classical negative feedback loop leading to decreased expression of iNOS, but may also restrict nitric oxide dependent cell death directly. In the absence of A20, enhanced NFκB activity may lead to increased expression of iNOS and increased production of reactive nitrogen species leading to greater DNA damage. In combination with enhanced nitric oxide dependent cell death in the absence of A20, carcinogenesis is amplified.
Table 1. Primers used in this study

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>msNOS2-5 Fwd</td>
<td>TCAGGAAGAAATGCAGGAGATG</td>
</tr>
<tr>
<td>msNOS2-5 Rev</td>
<td>TGAACGTAGACCTTGGTTTG</td>
</tr>
<tr>
<td>msA20 Fwd</td>
<td>CTGACCTGGTCTCTGAGGAAG</td>
</tr>
<tr>
<td>msA20 Rev</td>
<td>GAAAAGTCTCTGTTTCCACAA</td>
</tr>
<tr>
<td>msNFKBIA</td>
<td>TGAAGGACGAGGGAGTACGAGC</td>
</tr>
<tr>
<td>msNfkbia Rev</td>
<td>TGCAGGAACGAGTCTCCGT</td>
</tr>
<tr>
<td>msGAPDH-2 Fwd</td>
<td>AGGTCGGTGTGAACCGGATTTG</td>
</tr>
<tr>
<td>msGAPDH-2 Rev</td>
<td>TGTAGACCATGTAGTGGAGTTCA</td>
</tr>
</tbody>
</table>


5. L. Beaugerie, et al., Risk of Colorectal High-Grade Dysplasia and Cancer in a Prospective Observational Cohort of Patients With Inflammatory Bowel Disease. Gastroenterology 145, 166-175.e8 (2013).


